Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulators And Pharma Lock Horns On Pricing In India

Executive Summary

India's drugs price regulator and the pharmaceutical industry appear to be at loggerheads again, after the government indicated that it could consider introducing an "enabling clause" in the existing regulation that would facilitate fixing the prices of around 300 products where market data is not available.

You may also be interested in...



India’s Pricing Tussle Escalates After Regulator Names “Overcharging” Firms

Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.

Court Stays Controversial Indian Price Freeze

The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.

Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint

Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.

Topics

Latest News
UsernamePublicRestriction

Register

SC097218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel